MedTrace Logo

AT GOAL: Adopting Technology for Glucose Optimization and Lifestyle in Pregnancy

NCT05370612 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-03-31

Study results available
· View outcomes & findings →

Summary

This study will assess differences in patient preferences and glucose control between continuous glucose monitoring and standard glucose checks in pregnant patients with Type 2 Diabetes. 40 participants will be on study for approximately 182 days (26 weeks).

Conditions

  • Type2Diabetes
  • Pregnancy in Diabetic

Interventions

DEVICE

Dexcom G6 CGM

Dexcom 6 CGM, an FDA approved device. Sensors will be placed on the abdomen per package instruction to collect continuous glucose data. Experimental Group will wear CGM for the duration of their pregnancy. Control Group will have CGM data collected for 10 days at enrollment and at 28-32 weeks into their pregnancy.

OTHER

Participant Finger Stick Glucose Monitoring

Standard of care for individual participant

Sponsors & Collaborators

  • DexCom, Inc.

    collaborator INDUSTRY

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Jacquelyn H Adams, MD · UW School of Medicine and Public Health

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-08
Primary Completion
2024-10-06
Completion
2024-10-06
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05370612 on ClinicalTrials.gov